Conclusion: The assessment of bone health of CML patients on Imatinib should include both BMD tests and bone turnover marker assays such as CTX-1 and osteocalcin. This evidence concerns the gene BGLAP and chronic myelogenous leukemia, BCR-ABL1 positive.